Intuitive Surgical (NASDAQ:ISRG) is scheduled to announce Q4 earnings results on Tuesday, January 24th, after market close.

The consensus EPS Estimate is $1.25 (-3.8% Y/Y) and the consensus Revenue Estimate is $1.66B (+7.1% Y/Y).

Over the last 2 years, ISRG has beaten EPS estimates 88% of the time and has beaten revenue estimates 88% of the time.

Over the last 3 months, EPS estimates have seen 5 upward revisions and 3 downward. Revenue estimates have seen 1 upward revision and 3 downward.

On Jan. 11 Intuitive Surgical’s stock dipped -4.20% as the company disclosed its preliminary Q4 and full year 2022 revenue which fell short of consensus.

The company had said it expects Q4 revenue to grow +7% Y/Y to $1.66B (then consensus $1.69B) and FY revenue increase of +9% Y/Y to $6.22B (then consensus $6.26B).

Intuitive Surgical expects worldwide da Vinci procedures to increase about 12% to 16% in 2023.

The SA Quant Rating on ISRG is Hold, which is in contrast to the average Wall Street Analysts’ Rating of Buy. In the past one year, the stock has declined -5.36%. See chart here.

The company’s stock had risen +8.99% on Oct. 19 after it reported its Q3 results post market on Oct. 18. Both top and bottom line numbers had beaten analysts expectations.

Intuitive Surgical is among the Goldman Sachs potential stock picks for 2023 in the MedTech space, according to a report in December 2022. According to analysts, for 2023, the consensus revenue and margin projections in the subsector have been readjusted to reasonable levels, while valuations have reached more normal historicals after the pandemic-era “unusual premium” in 2019 – 2021.

Among notable news for Q4 was Intuitive Surgical signing a $1B share buyback agreement with Citibank.